Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) Director Bruno Lucidi sold 6,741 shares of the firm's stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $4.03, for a total value of $27,166.23. Following the transaction, the director owned 157,237 shares in the company, valued at $633,665.11. The trade was a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Bruno Lucidi also recently made the following trade(s):
- On Thursday, November 19th, Bruno Lucidi sold 22,619 shares of Atea Pharmaceuticals stock. The stock was sold at an average price of $3.94, for a total value of $89,118.86.
Atea Pharmaceuticals Price Performance
Shares of AVIR stock traded down $0.06 during mid-day trading on Thursday, hitting $3.93. The stock had a trading volume of 291,342 shares, compared to its average volume of 301,285. Atea Pharmaceuticals, Inc. has a 12-month low of $2.92 and a 12-month high of $6.45. The firm's 50-day moving average is $4.68 and its two-hundred day moving average is $4.94. The firm has a market capitalization of $315.58 million, a P/E ratio of -2.02 and a beta of 0.76.
Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.11. Analysts expect that Atea Pharmaceuticals, Inc. will post -1.60 EPS for the current year.
Atea Pharmaceuticals News Summary
Investors following AVIR have been watching these news items:
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in Atea Pharmaceuticals in the second quarter worth about $40,548,000. Arrowstreet Capital Limited Partnership bought a new stake in shares of Atea Pharmaceuticals in the 1st quarter valued at about $1,133,000. Hsbc Holdings PLC bought a new stake in shares of Atea Pharmaceuticals in the 2nd quarter valued at about $1,023,000. Bank of New York Mellon Corp bought a new stake in shares of Atea Pharmaceuticals in the 2nd quarter valued at about $881,000. Finally, Irenic Capital Management LP purchased a new position in shares of Atea Pharmaceuticals in the 1st quarter worth approximately $1,623,000. 86.67% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of research analysts have commented on the stock. Wall Street Zen raised shares of Atea Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, September 12th. Morgan Stanley upped their price target on shares of Atea Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a research report on Monday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Atea Pharmaceuticals in a research note on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $8.00.
Read Our Latest Research Report on Atea Pharmaceuticals
About Atea Pharmaceuticals
(
Get Free Report)
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication. The company's investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Atea Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atea Pharmaceuticals wasn't on the list.
While Atea Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.